12,372 trials
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Primary: Number of Participants With Adverse Events — 64; 19; 2; 1 Participants
Breast Cancer
Primary: Disease-free Survival (DFS) — 87.5; 85.8 percentage of patients — p=.31
Osteogenesis Imperfecta
Primary: Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline. — 25 Participants
Migraine, With or Without Aura
Primary: Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose — 14.3; 20.7; 21.8 percentage of participants — p=0.0285
Muscular Dystrophies
Primary: Change From Baseline in Muscle Function Using the 6 Minute Walking Distance (6MWD) Test Assessed at Week 48 — -52.65; -42.32 Meters — p=0.415
Influenza
Primary: Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies — 154; 121 Participants
Anesthesia
Primary: Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9 — 20.98; 3.72; 2.42; 0.58 Minutes
Prostate Cancer
Primary: The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease. — 126; 87; 88; 34 Participants
Severe Familial Hypercholesterolemia
Primary: Number of Participants With Adverse Events — 94; 174; 76; 143 Participants
Immune Thrombocytopenic Purpura
Primary: Number of Participants With Stable Platelet Response of at Least 50,000/µL — 9; 1 Participants — p=0.1519
Infections, Meningococcal
Primary: Number of Subjects With Vaccine Response for Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitides Serogroup A, C, W-135 and Y (rSBA-MenA…
Poliomyelitis · Tetanus · Acellular Pertussis
Primary: Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens — 105; 106; 105; 106 Participants
Asthma
Primary: Percentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24. — 56; 71…
Infections, Meningococcal
Primary: Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off. — 193; 180; 191; 178 Participants
FAP · Familial Amyloid Polyneuropathy · TTR
Primary: Change From Baseline In The Modified Neuropathy Impairment Score (mNIS) +7 Composite Score at Week 66 — 4.16; 23.89 Scores on a Scale — p=0.00000004